ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 26 filers reported holding ASCENDIS PHARMA A/S in Q1 2016. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,048,151 | +3.6% | 43,231 | -1.3% | 0.00% | 0.0% |
| Q2 2023 | $3,907,990 | +981.2% | 43,787 | +1198.9% | 0.00% | – |
| Q1 2023 | $361,438 | +13.0% | 3,371 | +28.7% | 0.00% | – |
| Q4 2022 | $319,980 | -65.1% | 2,620 | -70.5% | 0.00% | – |
| Q3 2022 | $918,000 | +551.1% | 8,893 | +486.2% | 0.00% | – |
| Q2 2022 | $141,000 | -77.7% | 1,517 | -71.8% | 0.00% | – |
| Q1 2022 | $631,000 | -26.5% | 5,381 | -15.7% | 0.00% | – |
| Q4 2021 | $859,000 | -45.4% | 6,381 | -35.4% | 0.00% | – |
| Q3 2021 | $1,574,000 | +8.4% | 9,872 | -10.5% | 0.00% | – |
| Q2 2021 | $1,452,000 | +268.5% | 11,034 | +260.8% | 0.00% | – |
| Q1 2021 | $394,000 | -27.7% | 3,058 | -6.4% | 0.00% | – |
| Q4 2020 | $545,000 | -52.2% | 3,266 | -55.8% | 0.00% | – |
| Q3 2020 | $1,141,000 | +112.1% | 7,393 | +103.0% | 0.00% | – |
| Q2 2020 | $538,000 | -55.3% | 3,642 | -65.9% | 0.00% | -100.0% |
| Q1 2020 | $1,203,000 | -37.8% | 10,683 | -23.2% | 0.00% | 0.0% |
| Q4 2019 | $1,934,000 | +189.5% | 13,903 | +100.5% | 0.00% | – |
| Q3 2019 | $668,000 | -5.9% | 6,934 | +12.5% | 0.00% | – |
| Q2 2019 | $710,000 | -78.4% | 6,164 | -77.9% | 0.00% | -100.0% |
| Q1 2019 | $3,287,000 | +635.3% | 27,916 | +291.4% | 0.00% | – |
| Q4 2018 | $447,000 | -55.9% | 7,133 | -50.1% | 0.00% | – |
| Q3 2018 | $1,014,000 | +57.0% | 14,305 | +47.3% | 0.00% | – |
| Q2 2018 | $646,000 | +46.8% | 9,713 | +44.2% | 0.00% | – |
| Q1 2018 | $440,000 | +169.9% | 6,734 | +65.7% | 0.00% | – |
| Q4 2017 | $163,000 | +757.9% | 4,064 | +689.1% | 0.00% | – |
| Q3 2017 | $19,000 | -29.6% | 515 | -46.3% | 0.00% | – |
| Q1 2017 | $27,000 | +575.0% | 959 | +379.5% | 0.00% | – |
| Q4 2016 | $4,000 | -77.8% | 200 | -78.2% | 0.00% | – |
| Q3 2016 | $18,000 | -30.8% | 918 | -35.2% | 0.00% | – |
| Q1 2016 | $26,000 | 0.0% | 1,417 | +0.9% | 0.00% | – |
| Q4 2015 | $26,000 | +85.7% | 1,404 | +78.2% | 0.00% | – |
| Q2 2015 | $14,000 | -6.7% | 788 | -8.9% | 0.00% | – |
| Q1 2015 | $15,000 | – | 865 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |